A Win For Small-Cell Lung Cancer: Impower 133

A Win for Small–Cell Lung Cancer: IMPOWER 133

Small-Cell Lung Cancer: The IMpower133 and CASPIAN trials

Small Cell Lung Cancer: Interpreting Data From IMpower133

Dr. Horn on Updated Data From IMpower133 in Small Cell Lung Cancer

IMpower133: atezolizumab, carboplatin plus etoposide for SCLC

IMpower133 in SCLC

First-line Immunotherapy: IMPower133 Regimen

Atezo maintenance therapy improves survival in the IMpower133 trial of ES-SCLC

Discussion of IMpower133 and CASPIAN Trials

Targeted Oncology

The CASPIAN Versus IMpower133 Regimen

Dr. Chen on the Impact of the Pivotal IMpower133 Trial on SCLC

Chemoimmunotherapy, the UK & extensive-stage SCLC

Highlights from WCLC 2018: NELSON, ALTA, IMpower133 & PACIFIC

Atezolizumab + Carboplatin/Etoposide for Extensive-Stage Small Cell Lung Cancer: IMpower133 Update

Frontline Therapy Approaches for Small Cell Lung Cancer

IMpower133 and CASPIAN Trials for Extensive Stage SCLC

Chemoimmunotherapy for ES SCLC: IMpower133 Trial

Optimal Management of Limited-Stage SCLC

Combining Immunotherapy and Chemotherapy in Patients With SCLC

Targeted Oncology

Addressing the Aggressive Nature of SCLC